Over one billion adults globally consume nicotine in one form or another, and over 200 million consume cannabinoids. In recent years the availability of nicotine products that provide stimulation at lower risk than traditional cigarettes have grown dramatically, and the regulation of cannabinoids is also changing with increased legalisation and availability.

Oral delivery products, noticeably tobacco free products for oral consumption have gained popularity over recent years, with over 100% CAGR globally since 2017. Xstimo is committed to offering safer alternatives to consumers around the world yet ensuring effective delivery of the active ingredient like nicotine, cannabidiols or other supplements and ensuring satisfying moments for the consumer.